<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03965429</url>
  </required_header>
  <id_info>
    <org_study_id>SIA-CSH-IPC 2015-017</org_study_id>
    <secondary_id>2019-000814-13</secondary_id>
    <nct_id>NCT03965429</nct_id>
  </id_info>
  <brief_title>Immunological Follow-up After Allogeneic Hematopoietic Stem Cell Transplantation</brief_title>
  <acronym>SIA-CSH</acronym>
  <official_title>Immunological Follow-up After Allogeneic Hematopoietic Stem Cell Transplantation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Institut Paoli-Calmettes</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>INSERM-U1068</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Institut Paoli-Calmettes</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Description of the evolution of the biological characteristics of immune blood populations
      and biomarkers of interest in patients who have received allogeneic hematopoietic stem cell
      transplantation.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      a more in-depth analysis of the different immune cell sub-populations as well as serum
      markers (cytokines) would provide a better understanding of post-allograft immune
      reconstitution mechanisms and identify potential immunologic biomarkers predictive of GVH or
      relapse.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 14, 2019</start_date>
  <completion_date type="Anticipated">May 31, 2029</completion_date>
  <primary_completion_date type="Anticipated">May 14, 2029</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Evolution of the immune blood populations in patients who have received allogeneic hematopoietic stem cell transplantation.</measure>
    <time_frame>5 years after HSC transplantation</time_frame>
    <description>longitudinal study of the immune subpopulations of allografted patients for hematological malignancies.</description>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">1020</enrollment>
  <condition>Malignant Hemopathy</condition>
  <arm_group>
    <arm_group_label>Donor</arm_group_label>
    <description>In the case of a transplant from an intrafamily donor (genoid or haploid), we will also collect blood samples from the donor.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Receiver</arm_group_label>
    <description>Systematic longitudinal collection of blood samples for any patient receiving an allogeneic CSH transplant in our facility, regardless of donor category selected and type of graft used</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Blood samples (additional tubes from care) longitudinal</intervention_name>
    <description>Some sampling times will be systematic, while others will only be performed in the presence of specific post-transplant clinical events (eg relapse, GVH ...).</description>
    <arm_group_label>Receiver</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Blood samples (additional tubes from care) at inclusion</intervention_name>
    <description>In the case of a transplant from an intrafamily donor (genoid or haploid), we will also collect blood samples from the donor. A single blood sample of 28 mL (7 EDTA tubes) will be made.
In order not to represent an additional sample for the donor, this sample will be taken before the mobilization of the hematopoietic stem cells, during the biological assessment required for the biological donation qualification.</description>
    <arm_group_label>Donor</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Systematic longitudinal collection of blood samples for any patient receiving an allogeneic
      CSH transplant in our facility, regardless of donor category selected and type of graft used
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        The study population is male and / or female over 18 years of age with hematologic
        malignancies receiving allogeneic hematopoietic stem cell transplantation and corresponding
        donors.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Allogeneic hematopoietic stem cell transplant for hematological malignancy

          2. Patients 18 years of age or older

          3. Signed consent to participation

          4. Membership in a social security scheme, or beneficiary of such a scheme.

        Exclusion Criteria:

          -  A person of legal age subject to a legal protection measure (major under guardianship,
             curatorship or court bail), or unable to express consent (language criteria included).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Raynier Devillier, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Institut Paoli-Calmettes</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Dominique Genre, MD</last_name>
    <phone>0491223778</phone>
    <email>drci.up@ipc.unicancer.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Margot Berline, MSc, MBA</last_name>
    <phone>0491223314</phone>
    <email>drci.up@ipc.unicancer.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Institut Paoli-Calmettes</name>
      <address>
        <city>Marseille</city>
        <state>Bouches-du Rh√¥ne</state>
        <zip>13009</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dominique GENRE, MD</last_name>
      <phone>+33 4 91 22 37 78</phone>
      <email>drci.up@ipc.unicancer.fr</email>
    </contact>
    <investigator>
      <last_name>Raynier DEVILLIER</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>May 2019</verification_date>
  <study_first_submitted>May 16, 2019</study_first_submitted>
  <study_first_submitted_qc>May 28, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">May 29, 2019</study_first_posted>
  <last_update_submitted>May 28, 2019</last_update_submitted>
  <last_update_submitted_qc>May 28, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">May 29, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>malignant hemopathy</keyword>
  <keyword>allogeneic hematopoietic stem cell transplant</keyword>
  <keyword>blood collection</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

